These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12065874)

  • 21. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
    Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
    J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
    Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
    Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
    PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
    Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
    Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
    Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
    Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma.
    Leiter U; Schmid RM; Kaskel P; Peter RU; Krähn G
    Arch Dermatol Res; 2000 May; 292(5):225-32. PubMed ID: 10867810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
    Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
    Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic significance of some markers in cutaneous melanoma treated with different therapeutic modalities].
    Nepomniashchaia EM; Gusareva MA; Petrov SV
    Vopr Onkol; 2008; 54(6):744-8. PubMed ID: 19241851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
    Divito KA; Berger AJ; Camp RL; Dolled-Filhart M; Rimm DL; Kluger HM
    Cancer Res; 2004 Dec; 64(23):8773-7. PubMed ID: 15574790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
    Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
    Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer.
    Takayama K; Ogata K; Nakanishi Y; Yatsunami J; Kawasaki M; Hara N
    Cancer J Sci Am; 1996; 2(4):212-6. PubMed ID: 9166534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
    Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
    Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions.
    Korabiowska M; Brinck U; Mirecka J; Kellner S; Marx D; Schauer A
    In Vivo; 1995; 9(5):433-8. PubMed ID: 8900920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins.
    Zhuang L; Scolyer RA; Murali R; McCarthy SW; Zhang XD; Thompson JF; Hersey P
    Mod Pathol; 2010 Jan; 23(1):45-53. PubMed ID: 19838163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
    Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
    Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.